These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29936373)

  • 1. Unraveling the mysteries of modern size exclusion chromatography - the way to achieve confident characterization of therapeutic proteins.
    Goyon A; Fekete S; Beck A; Veuthey JL; Guillarme D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1092():368-378. PubMed ID: 29936373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
    Goyon A; D'Atri V; Colas O; Fekete S; Beck A; Guillarme D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1065-1066():35-43. PubMed ID: 28946123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of size exclusion chromatography columns packed with sub-3μm particles for the analysis of biopharmaceutical proteins.
    Goyon A; Beck A; Colas O; Sandra K; Guillarme D; Fekete S
    J Chromatogr A; 2017 May; 1498():80-89. PubMed ID: 27914608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products.
    Ehkirch A; Hernandez-Alba O; Colas O; Beck A; Guillarme D; Cianférani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():176-183. PubMed ID: 29684909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending the limits of size exclusion chromatography: Simultaneous separation of free payloads and related species from antibody drug conjugates and their aggregates.
    Goyon A; Sciascera L; Clarke A; Guillarme D; Pell R
    J Chromatogr A; 2018 Mar; 1539():19-29. PubMed ID: 29397979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of system band broadening in modern size exclusion chromatography.
    Goyon A; Guillarme D; Fekete S
    J Pharm Biomed Anal; 2017 Feb; 135():50-60. PubMed ID: 27992782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High resolution separation of recombinant monoclonal antibodies by size-exclusion ultra-high performance liquid chromatography (SE-UHPLC).
    Yang R; Tang Y; Zhang B; Lu X; Liu A; Zhang YT
    J Pharm Biomed Anal; 2015 May; 109():52-61. PubMed ID: 25766848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of being metal-free: The critical choice of column hardware for size exclusion chromatography coupled to high resolution mass spectrometry.
    Murisier A; Fekete S; Guillarme D; D'Atri V
    Anal Chim Acta; 2021 Oct; 1183():338987. PubMed ID: 34627511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A native SEC-MS workflow and validation for analyzing drug-to-antibody ratio and drug load distribution in cysteine-linked antibody-drug conjugates.
    Wu G; Yu C; Yin S; Du J; Zhang Y; Fu Z; Wang L; Wang J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124167. PubMed ID: 38823148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocols for the analytical characterization of therapeutic monoclonal antibodies. I - Non-denaturing chromatographic techniques.
    Goyon A; D'Atri V; Bobaly B; Wagner-Rousset E; Beck A; Fekete S; Guillarme D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jul; 1058():73-84. PubMed ID: 28549280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates.
    Bobály B; Fleury-Souverain S; Beck A; Veuthey JL; Guillarme D; Fekete S
    J Pharm Biomed Anal; 2018 Jan; 147():493-505. PubMed ID: 28688616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry.
    Haberger M; Leiss M; Heidenreich AK; Pester O; Hafenmair G; Hook M; Bonnington L; Wegele H; Haindl M; Reusch D; Bulau P
    MAbs; 2016; 8(2):331-9. PubMed ID: 26655595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-Dimensional Liquid Chromatography Coupled to High-Resolution Mass Spectrometry for the Analysis of ADCs.
    Chapel S; Rouvière F; Sarrut M; Heinisch S
    Methods Mol Biol; 2020; 2078():163-185. PubMed ID: 31643056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
    Friese OV; Smith JN; Brown PW; Rouse JC
    MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of ADCs by Native Mass Spectrometry.
    Hernandez-Alba O; Ehkirch A; Beck A; Cianférani S
    Methods Mol Biol; 2020; 2078():197-211. PubMed ID: 31643058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization.
    Terral G; Beck A; Cianférani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():79-90. PubMed ID: 27108304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of thiol-to-protein ratio and drug-to-antibody ratio by in-line size exclusion chromatography with post-column reaction.
    Furuki K; Toyo'oka T
    Anal Biochem; 2017 Jun; 527():33-44. PubMed ID: 28432000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size exclusion chromatography of biopharmaceutical products: From current practices for proteins to emerging trends for viral vectors, nucleic acids and lipid nanoparticles.
    D'Atri V; Imiołek M; Quinn C; Finny A; Lauber M; Fekete S; Guillarme D
    J Chromatogr A; 2024 May; 1722():464862. PubMed ID: 38581978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size-exclusion chromatography-mass spectrometry with m-nitrobenzyl alcohol as post-column additive for direct characterization of size variants of monoclonal antibodies.
    Xu CF; Zang L; Weiskopf A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():230-8. PubMed ID: 24835510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.
    Deslignière E; Diemer H; Erb S; Coliat P; Pivot X; Detappe A; Hernandez-Alba O; Cianférani S
    Front Biosci (Landmark Ed); 2022 Oct; 27(10):290. PubMed ID: 36336868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.